Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lyconize is a multi-ingredient antioxidant dietary supplement developed and marketed by SBM Enterprises (also known as SBM Pharmaceuticals). It is available as a finished formulation in softgel capsule form. The product contains a combination of active ingredients including lycopene (an antioxidant carotenoid), black grape seed extract, lutein, beta-carotene, and selenium dioxide monohydrate, along with various vitamins and minerals. According to the company's product information, the formulation contains lycopene 10% USP 4000mcg, black grape seed extract 10mg, lutein 10% USP 4000 mcg, beta-carotene 30% USP 5.17mg, and selenium dioxide monohydrate USP 25 mcg. This product is marketed for general nutritional supplementation and antioxidant support. As a finished formulation marketed by a PCD (Propaganda Cum Distribution) pharma company, it is positioned as a branded generic nutraceutical rather than an investigational pharmaceutical drug.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lyconize.